QUICK ANSWER · AEO / GEO
Botulinum toxin is a neurotoxin protein, not SNAP-8 or a dermal filler. This overview focuses on type A: Class A and Grade A refer only to authorised products and studied indications, not an unverified supplier vial. BOTOX is a specific brand; potency units are not interchangeable across products. Controlled studies support selected glabellar-line and chronic-migraine outcomes, not all wrinkle or headache claims. Thai FDA BOTOX record 1C 21/55 (NB) and EU Nuceiva authorisation are product-specific examples. MHRA's July 2026 warning highlights rare, potentially life-threatening iatrogenic botulism. Breathing, swallowing or speech difficulties after treatment require emergency medical attention.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
Insufficient data in the current dataset
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pubmed.ncbi.nlm.nih.gov/12063480/
- https://pubmed.ncbi.nlm.nih.gov/20487038/
- https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300&type=display
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C10B2550002111C
- https://www.ema.europa.eu/en/medicines/human/EPAR/nuceiva
- https://www.gov.uk/drug-safety-update/botulinum-toxin-type-a-products-updated-warnings-regarding-risk-of-iatrogenic-botulism
- https://www.fda.gov/news-events/press-announcements/fda-warns-companies-over-illegal-marketing-botox-and-related-products
FAQ · ANSWER ENGINE
Frequently asked questions
What is Botulinum toxin?
Botulinum toxin is described pharmacologically as Botulinum neurotoxin protein / acetylcholine release inhibitor; type A product-specific review. Botulinum toxin is a neurotoxin protein, not SNAP-8 or a dermal filler. This overview focuses on type A: Class A and Grade A refer only to authorised products and studied indications, not an unverified supplier vial. BOTOX is a specific brand; potency units are not interchangeable across products. Controlled studies support selected glabellar-line and chronic-migraine outcomes, not all wrinkle or headache claims. Thai FDA BOTOX record 1C 21/55 (NB) and EU Nuceiva authorisation are product-specific examples. MHRA's July 2026 warning highlights rare, potentially life-threatening iatrogenic botulism. Breathing, swallowing or speech difficulties after treatment require emergency medical attention.
Does Botulinum toxin have strong evidence?
PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Botulinum toxin approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.